GlobalData Plc
Tagged: / /

Following today’s news (19 December 2018) that the EU is implementing a ‘no deal’ Brexit plan, Alexandra Annis, Pharma analyst at GlobalData offers her view:

“This news does not come as a surprise as 38% of respondents from GlobalData’s recent report ‘Brexit and the Healthcare Industry – Implications for Pharma, Q3 2018’ indicated a ‘no deal’ Brexit is the most likely outcome. However, this does not mean the EU is planning for the best outcome of Brexit. Only 5% of respondents indicated a ‘no deal’ Brexit is the best outcome while 60% of respondents indicated no Brexit is the best outcome.

“This news follows decreasing sentiment on the impact of Brexit on the healthcare sector, as 59% of respondents indicated their sentiment has become more negative when polled in June 2018. A ‘no deal’ Brexit has the potential to substantially impact the UK healthcare industry with major concerns around the regulatory implications of the UK leaving the EEA, disruption to cross-EU drug supply chain, and funding for research and manufacturing.”

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF